Finally, DCs in human breast cancers have been shown to express CXCL9,43 and CXCL9 expression correlates with response to anti-PD-1 therapy,44 further suggesting a role for DCs in the context of patient response to anti-PD-1. Here, CXCL9 is linked to breast carcinoma.